Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Zafgen, Inc. and Lead Plaintiff Deadline and December 21, 2015

NEW YORK, Dec. 2, 2015

The complaint alleges that Zafgen made false and/or misleading statements and/or failed to disclose to investors that: (i) one participant in the beloranib Phase 3 study, who had died, was receiving beloranib and not a placebo; (ii) while Zafgen had reported 2 thrombotic events in prior clinical studies, there had actually been 4 such events, as well as 2 additional thrombotic events in other ongoing studies; and (iii) consequently, Defendants' statements about Zafgen's business, operations and prospects were false and misleading and/or lacked a reasonable basis.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.  If you suffered a loss in Zafgen you have until December 21, 2015 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com